SGLT2 inhibition does not reduce glucose absorption during experimental peritoneal dialysis

Area of Science:

• Nephrology
• Endocrinology
• Pharmacology

Background:

• Unwanted glucose absorption during peritoneal dialysis (PD) poses a challenge, particularly for diabetic patients.
• Sodium-glucose co-transporter 2 (SGLT2) inhibitors were investigated for their potential to reduce glucose uptake during PD.
• The study explored whether glucose absorption occurs via intracellular or trans-cellular pathways.

Purpose of the Study:

• To evaluate the effects of SGLT2 inhibition using empagliflozin on peritoneal water and solute transport during experimental PD in rats.
• To assess glucose absorption and diffusion capacity during PD under SGLT2 inhibition.
• To investigate the role of SGLT2 in glucose transport across the peritoneal membrane.

Main Methods:

• Peritoneal dialysis was performed in anesthetized Sprague-Dawley rats using 1.5% or 4.25% glucose solutions.
• Empagliflozin was administered to assess the impact of SGLT2 inhibition on glucose absorption.
• A modified equation was used to measure small solute diffusion capacity, accounting for convective and free water transport.

Main Results:

• SGLT2 inhibition increased urinary glucose excretion and lowered plasma glucose post-PD.
• No significant reduction in glucose absorption was observed in empagliflozin-treated rats compared to sham groups for both 1.5% and 4.25% glucose solutions.
• There were no significant changes in sodium or water transport across the peritoneal barrier.

Conclusions:

• Recent findings suggesting SGLT2 inhibition reduces glucose absorption during experimental PD could not be confirmed.
• Empagliflozin did not significantly alter glucose absorption or osmotic water transport in this rat model of PD.
• The study indicates SGLT2 inhibition may not be an effective strategy to reduce glucose absorption during PD.